Studies in rodents with the dipeptidyl peptidase-4 inhibitor vildagliptin to evaluate possible drug-induced pancreatic histological changes that are predictive of pancreatitis and cancer development in man

Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans

(2011) B. Ahrén et al.   DIABETES OBESITY & METABOLISM

Beta cell function following 1 year vildagliptin or placebo treatment and after 12 week washout in drug-naive patients with type 2 diabetes and mild hyperglycaemia: a randomised controlled trial

(2011) J. E. Foley et al.   DIABETOLOGIA

Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1–Based Therapies

(2011) Michael Elashoff et al.   GASTROENTEROLOGY

The DPP-4 inhibitor vildagliptin increases pancreatic beta cell mass in neonatal rats

(2010) Alokesh Duttaroy et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Cancer: Genomic evolution of metastasis

(2010) E. Georg Luebeck   NATURE

The patterns and dynamics of genomic instability in metastatic pancreatic cancer

(2010) Peter J. Campbell et al.   NATURE

Distant metastasis occurs late during the genetic evolution of pancreatic cancer

(2010) Shinichi Yachida et al.   NATURE

Beneficial Endocrine but Adverse Exocrine Effects of Sitagliptin in the Human Islet Amyloid Polypeptide Transgenic Rat Model of Type 2 Diabetes: Interactions With Metformin

(2009) A. V. Matveyenko et al.   DIABETES